Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Atrial Shunt for the Treatment of Heart Failure With Reduced Ejection Fraction (PAST-HFrEF)

9. September 2026 aktualisiert von: Guangyuan Song, Beijing Anzhen Hospital

A Prospective, Randomized, Open-Label, Parallel-Controlled, Superiority, Multicenter Clinical Study of Atrial Shunt for the Treatment of Heart Failure With Reduced Ejection Fraction

To evaluate the safety and effectiveness of the Atrial Shunt for the treatment of heart failure with reduced ejection fraction (HFrEF)

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This is a prospective, randomized, open-label, parallel-controlled, superiority, multicenter clinical study. A total of 208 subjects will be randomized 1:1 after meeting all inclusion/exclusion criteria.

Treatment Group: atrial shunt implantation post-right heart catheterization. Control Group: Right heart catheterization only. Both groups will receive standardized Guideline-Directed Medical Therapy (GDMT) post-procedure. Assessments and follow-ups will be conducted at pre-procedure baseline, day of procedure, 1 week, 1 month, 3 months, 6 months, and 12 months post-procedure.

A Clinical Event Committee (CEC), composed of third-party cardiovascular experts, will independently review and adjudicate primary endpoints in a blinded manner (surgical information concealed).

Studientyp

Interventionell

Einschreibung (Geschätzt)

208

Phase

  • Phase 2
  • Phase 3

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100029
        • Rekrutierung
        • Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • 1. Age ≥ 18 years 2. Diagnosed with HFrEF and receiving Guideline-Directed Medical Therapy (GDMT) for at least 1 month 3. Echocardiographic LVEF between 20% and 40% (20 ≤ LVEF ≤ 40%) 4. Presence of HF-related symptoms and signs, NYHA Class III 5. At least one HF-related hospitalization in the past year or NT-proBNP ≥ 600 pg/mL (sinus rhythm) / ≥ 1000 pg/mL (atrial fibrillation) 6. Invasive hemodynamics: mLAP or mPCWP ≥ 15 mmHg, or left-to-right mean pressure gradient ≥ 5 mmHg 7. Fully understand the study design and follow-up schedule, agrees to participate, and voluntarily signs the Informed Consent Form

Exclusion Criteria:

  • 1. End-stage heart failure on the heart transplant waiting list (including meeting LVAD indications) 2. Three consecutive non-invasive systolic blood pressure readings < 90 mmHg 3. Primary structural valvular disease currently indicating surgery or interventional therapy, or severe coronary artery disease requiring revascularization 4. ECG QRS duration ≥ 130 ms with high risk of sudden cardiac death without therapeutic intervention (including meeting CRT/CRT-D indications) 5. Significant right ventricular (RV) dysfunction or severe pulmonary hypertension. Defined by clinical evidence of hepatic congestion, moderate-to-severe edema, or abdominal distension accompanied by poor appetite; significant right atrial or RV enlargement/dysfunction; moderate-to-severe tricuspid regurgitation; mean right atrial pressure > 10 mmHg; systolic pulmonary artery pressure > 60 mmHg; or pulmonary vascular resistance > 3 Wood Units 6. Myocardial infarction or cardiac intervention within the past 1 month 7. Stroke within the past 1 month (excluding lacunar infarction) 8. Decompensated liver cirrhosis (Child-Pugh Class B or worse), or severe chronic pulmonary disease requiring oxygen therapy 9. Anatomical abnormalities precluding procedure completion or making the patient unsuitable for procedure 10. Atrial thrombosis 11. Contraindication to antithrombotic therapy 12. Life expectancy < 1 year 13. Uncontrolled active infection 14. Pregnant, lactating, or women of childbearing potential planning pregnancy in the near future 15. Currently participating in another drug or medical device clinical trial 16. Investigator deems the patient unsuitable for this trial

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Single

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Device group (Interventional group)
Patients will receive atrial shunt for heart failure treatment plus maximally tolerated guideline-directed medical therapy for cardiovascular disease
Gerät: D-shant Atrial Shunt
The D-Shant atrial shunt device is a novel device therapy for heart failure, classified as a non-active implantable cardiovascular device. It is manufactured using a braided Nitinol technique, thermally set via assembly molds to form a waist with a fixed-orifice support and a hollow double-disc structure. Braided wires reinforce waist support and maintain a circular orifice shape. Once implanted, it forms a stable interatrial shunt. The device is delivered via the femoral vein to the interatrial septum, where the shunt orifice facilitates blood flow diversion and pressure decompression. Various models with different waist and disc diameters are available to accommodate varying degrees and etiologies of heart failure.
Arzneimittel: Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction
Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction
Aktiver Komparator: no Device group (Control Group)
Patients will receive maximally tolerated guideline-directed medical therapy for heart failure only
Arzneimittel: Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction
Guideline-Directed Medical Therapy (GDMT) for heart failure with reduced ejection fraction

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
A composite event of all-cause mortality, heart transplantation or left ventricular assist device implantation due to heart failure, heart failure-related rehospitalization post-procedure and Unplanned outpatient worsening heart failure within 12 months
Zeitfenster: From enrollment to the end of treatment at 12 months
A composite event of all-cause mortality, heart transplantation or left ventricular assist device implantation due to heart failure, heart failure-related rehospitalization post-procedure and Unplanned outpatient worsening heart failure within 12 months. Hospitalization for heart failure requires an admission to an in-patient unit or an emergency room stay for ≥24 hours (or <24 hours if subject dies in the emergency room). - Outpatient worsening heart failure requires an unplanned visit to a doctor's office, urgent care center or emergency room visit with stay <24 hours. - Worsening heart failure must be present for both conditions, the definition of which requires all three of the following to be present: 1. Deterioration of HF symptoms: at least 1 of the following symptoms 2. Deterioration of HF signs: 2 physical examination findings or 1 physical examination + 1 laboratory or invasive finding 3. Urgent escalation of therapy
From enrollment to the end of treatment at 12 months

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
6-minute walk distance (6MWD) (0-1000m, higher scores indicate a better outcome）
Zeitfenster: From enrollment to the end of treatment at 12 months
Change in exercise capacity post-procedure: 6-Minute Walk Test
From enrollment to the end of treatment at 12 months
New York Heart Association (NYHA) Functional Classification (I-IV, higher scores indicate a worse outcome）
Zeitfenster: From enrollment to the end of treatment at 12 months
Change in New York Heart Association (NYHA) Functional Classification
From enrollment to the end of treatment at 12 months
Change in NT-proBNP levels
Zeitfenster: From enrollment to the end of treatment at 12 months
Change in NT-proBNP levels
From enrollment to the end of treatment at 12 months
Left atrial diameter
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic Left atrial diameter
From enrollment to the end of treatment at 12 months
Device Success Rates (Treatment Group)
Zeitfenster: From enrollment to the end of treatment at 12 months
Device Success is defined as successful implantation of the shunt with normal morphology and position, visible left-to-right shunt on echocardiography, and an immediate decrease in mean Left Atrial Pressure (mLAP) or mean Pulmonary Capillary Wedge Pressure (mPCWP) compared to pre-implantation.
From enrollment to the end of treatment at 12 months
Changes in 12-lead Electrocardiogram (ECG)
Zeitfenster: From enrollment to the end of treatment at 12 months
Presence of arrhythmias
From enrollment to the end of treatment at 12 months
Shunt Orifice Patency/Occlusion Status (Treatment Group)
Zeitfenster: From enrollment to the end of treatment at 12 months
Shunt Orifice Patency/Occlusion Status (Treatment Group)
From enrollment to the end of treatment at 12 months
All-cause mortality rate
Zeitfenster: From enrollment to the end of treatment at 12 months
All-cause mortality rate
From enrollment to the end of treatment at 12 months
Number of HF-related rehospitalizations post-procedure
Zeitfenster: From enrollment to the end of treatment at 12 months
Number of HF-related rehospitalizations post-procedure
From enrollment to the end of treatment at 12 months
Kansas City Cardiomyopathy Questionnaire (KCCQ) score (0-100, higher scores indicate a better outcome）
Zeitfenster: From enrollment to the end of treatment at 12 months
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) score
From enrollment to the end of treatment at 12 months
Right atrial diameter
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic right atrial diameter
From enrollment to the end of treatment at 12 months
Left ventricular diameter
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic left ventricular diameter
From enrollment to the end of treatment at 12 months
Right ventricular diameter
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic reft atrial diameter
From enrollment to the end of treatment at 12 months
Left Ventricular Ejection Fraction
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic Left Ventricular Ejection Fraction
From enrollment to the end of treatment at 12 months
Tricuspid Annular Plane Systolic Excursion
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic Tricuspid Annular Plane Systolic Excursion
From enrollment to the end of treatment at 12 months
Right Ventricular Fractional Area
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic Right Ventricular Fractional Area
From enrollment to the end of treatment at 12 months
Aortic regurgitation
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic aortic regurgitation
From enrollment to the end of treatment at 12 months
Mitral regurgitation
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic mitral regurgitation
From enrollment to the end of treatment at 12 months
Tricuspid regurgitation
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic tricuspid regurgitation
From enrollment to the end of treatment at 12 months
Shunt orifice diameter
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic Shunt orifice diameter
From enrollment to the end of treatment at 12 months
Shunt flow velocity
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic shunt flow velocity
From enrollment to the end of treatment at 12 months
Trans-shunt pressure gradient
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic trans-shunt pressure gradient
From enrollment to the end of treatment at 12 months
Shunt flow direction
Zeitfenster: From enrollment to the end of treatment at 12 months
Echocardiographic shunt flow direction
From enrollment to the end of treatment at 12 months
Procedural Success Rates (Treatment Group)
Zeitfenster: From enrollment to the end of treatment at 12 months
Procedural Success is defined as achieving Device Success with the patient surviving to hospital discharge.
From enrollment to the end of treatment at 12 months

Andere Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Device-Related Adverse Events
Zeitfenster: From enrollment to the end of treatment at 12 months
Cardiac tamponade Air embolism Systemic embolization syndrome Thrombus formation on the device surface Device malfunction requiring emergency surgical removal
From enrollment to the end of treatment at 12 months

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Beijing Anzhen Hospital

Mitarbeiter

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Ermittler

  • Hauptermittler: Guangyuan Song, M.D., Beijing Anzhen Hospital

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

25. November 2024

Primärer Abschluss (Geschätzt)

31. Dezember 2027

Studienabschluss (Geschätzt)

31. Dezember 2027

Studienanmeldedaten

Zuerst eingereicht

16. Juli 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. September 2026

Zuerst gepostet (Tatsächlich)

15. September 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

15. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

9. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Andere Studien-ID-Nummern

  • BeijingAnzhen20260716

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren